
    
      XZP-5849 is a selective phosphodiesterase (PDE5) inhibitor. The proposed randomized Phase 1
      trial is a double-blind, placebo-controlled, single ascending dose study in approximately 66
      Chinese healthy adult male subjects. The study consists of 8 cohorts (1 cohort per dose
      level). Each subject will participate in only one cohort.
    
  